Profusa Raised $45M To Market PAD-Monitoring Implant In Europe
Executive Summary
Digital Health company Profusa raised more than $45m in a series C financing round. The company plans to use the proceeds to bring its tiny CE-marked injectable biosensors, used to monitor tissue oxygenation in patients with peripheral artery disease, to key opinion leaders and clinicians in Europe.
You may also be interested in...
Podcast: Beyond Wearables--Profusa CEO Discusses Novel Tiny Injectable Biosensor For Long-Term Monitoring
In this podcast interview with Medtech Insight, Profusa Inc. Chairman and CEO Ben Hwang discusses the company's long-term biochemical monitoring platform, the first application for its tiny injectable biosensor, and what's next for the company.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.